Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors

Abstract

Background. Activating mutations in Kit receptor tyrosine kinase or the related platelet-derived growth factor receptor (PDGFR) play an important role in the pathogenesis of gastrointestinal stromal tumors (GIST). Methods. This study investigated the activity of motesanib, an inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3; PDGFR; and Kit, against primary activating Kit mutants and mutants associated with secondary resistance to imatinib. Single- and double-mutant isoforms of Kit were evaluated for their sensitivity to motesanib or imatinib in autophosphorylation assays and in Ba/F3 cell proliferation assays. Results. Motesanib inhibited Kit autophosphorylation in CHO cell lines expressing primary activating mutations in exon 9 (AYins503-504, IC50= 18 nM) and exon 11 (V560 D, IC50= 5 nM; 552-559, IC50= 1 nM). Motesanib also demonstrated activity against kinase domain mutations conferring imatinib resistance (V560D/V654A, IC50= 77 nM; V560D/T670I, IC50= 277 nM; Y823 D, IC 50= 64 nM) but failed to inhibit the imatinib-resistant D816V mutant (IC50 3000 nM). Motesanib suppressed the proliferation of Ba/F3 cells expressing Kit mutants with IC50values in good agreement with those observed in the autophosphorylation assays. Conclusions. In conclusion, our data suggest that motesanib possesses inhibitory activity against primary Kit mutations and some imatinib-resistant secondary mutations. © 2010 Caenepeel et al; licensee BioMed Central Ltd.